Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 4/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | TXK | P42681 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | ITK | Q08881 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | VDR | P11473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5950522 | 0.85 | ESR1 (0.40) | CHRM3CYP1A2CYP2C9CYP2C19CNR2 | |
| SCHEMBL1599127 | 0.78 | AR (0.47) | LMNAAR | |
| SCHEMBL5160005 | 0.78 | LMNA (0.50) | CYP1A2CYP2C9CYP2C19CNR2LMNA | |
| SCHEMBL4379660 | 0.78 | ALDH1A1 (0.44) | LMNAESR1ESR2 | |
| SCHEMBL629909 | 0.77 | ESR1 (0.38) | ESR1SYKESR2 | |
| SCHEMBL14253997 | 0.76 | CHRM3 (0.33) | CHRM3CYP1A2CYP2C9CYP2C19CNR2 | |
| SCHEMBL2716555 | 0.76 | TSHR (0.50) | CYP1A2CYP2C9CYP2C19CNR2 | |
| SCHEMBL1525128 | 0.76 | CA1 (0.41) | CHRM3 | |
| SCHEMBL14922832 | 0.76 | CYP1A2 (0.41) | CYP1A2CYP2C9CYP2C19CNR2LMNA | |
| SCHEMBL6037776 | 0.74 | HRH3 (0.39) | CHRM3CYP1A2CYP2C9CYP2C19ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112106-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112106-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112106-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-7919621-B2 | Tricyclic inhibitors of 5-lipoxygenase | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919621-B2 | Tricyclic inhibitors of 5-lipoxygenase | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919621-B2 | Tricyclic inhibitors of 5-lipoxygenase | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-1978966-A2 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | Amira Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007087250-A2 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007087250-A2 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-7071178-B2 | Use of vitamin D-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin D3-derivatives | LEO PHARMACEUTICAL PRODUCTS, LTD. (DK) | 2006-07-04 | — | — | US | disclosed |
| US-20040069523-A1 | Use of Vitamin D-Derivatives in the Treatment of Osteoporosis and related bone disorders, as well as novel vitamin D3-Deviratives | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2004-04-15 | — | — | US | disclosed |
| EP-1255732-A1 | USE OF VITAMIN D-DERIVATIVES IN THE TREATMENT OF OSTEOPOROSIS AND RELATED BONE DISORDERS, AS WELL AS NOVEL VITAMIN D3-DERIVATIVES | Leo Pharma A/S (DK) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001056981-A1 | USE OF VITAMIN D-DERIVATIVES IN THE TREATMENT OF OSTEOPOROSIS AND RELATED BONE DISORDERS, AS WELL AS NOVEL VITAMIN D3-DERIVATIVES | LEO PHARMA A/S (DK) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | ALOX5, ALOX15, ALOX15B | CHRM3 2250/4885CYP1A2 189/4885CYP2C9 224/4885 |
| US-20110112106-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | ALOX5, ALOX15, ALOX15B | CHRM3 2250/4885CYP1A2 189/4885CYP2C9 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.